JP2002531498A - イオンチャネル活性剤としてのイサチン誘導体の使用方法 - Google Patents

イオンチャネル活性剤としてのイサチン誘導体の使用方法

Info

Publication number
JP2002531498A
JP2002531498A JP2000586327A JP2000586327A JP2002531498A JP 2002531498 A JP2002531498 A JP 2002531498A JP 2000586327 A JP2000586327 A JP 2000586327A JP 2000586327 A JP2000586327 A JP 2000586327A JP 2002531498 A JP2002531498 A JP 2002531498A
Authority
JP
Japan
Prior art keywords
oxime
dione
indole
group
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2000586327A
Other languages
English (en)
Japanese (ja)
Other versions
JP2002531498A5 (enExample
Inventor
ジェンセン・ボー・スカーニング
イェルゲンセン・チノ・ディーリング
アーリング・フィリップ・ケイ
クリストファーセン・パルレ
ストロベック・ドルテ
トイバー・レネ
オレセン・セーレン・ペーター
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
NTG Nordic Transport Group AS
Original Assignee
Neurosearch AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurosearch AS filed Critical Neurosearch AS
Publication of JP2002531498A publication Critical patent/JP2002531498A/ja
Publication of JP2002531498A5 publication Critical patent/JP2002531498A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56—Ring systems containing three or more rings
    • C07D209/58—[b]- or [c]-condensed
    • C07D209/60—Naphtho [b] pyrroles; Hydrogenated naphtho [b] pyrroles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/12—Antidiarrhoeals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Endocrinology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Psychiatry (AREA)
  • Reproductive Health (AREA)
  • Vascular Medicine (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
JP2000586327A 1998-12-04 1999-12-03 イオンチャネル活性剤としてのイサチン誘導体の使用方法 Pending JP2002531498A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DK199801608 1998-12-04
DKPA199801608 1998-12-04
PCT/DK1999/000679 WO2000033834A1 (en) 1998-12-04 1999-12-03 Use of isatin derivatives as ion channel activating agents

Publications (2)

Publication Number Publication Date
JP2002531498A true JP2002531498A (ja) 2002-09-24
JP2002531498A5 JP2002531498A5 (enExample) 2007-01-25

Family

ID=8106503

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2000586327A Pending JP2002531498A (ja) 1998-12-04 1999-12-03 イオンチャネル活性剤としてのイサチン誘導体の使用方法

Country Status (7)

Country Link
US (2) US20020016354A1 (enExample)
EP (1) EP1135123B1 (enExample)
JP (1) JP2002531498A (enExample)
AT (1) ATE285769T1 (enExample)
AU (1) AU1648600A (enExample)
DE (1) DE69922997T2 (enExample)
WO (1) WO2000033834A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009227624A (ja) * 2008-03-24 2009-10-08 Fujifilm Corp 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1736468A3 (en) * 2000-01-24 2007-01-03 NeuroSearch A/S Isatin derivatives with neurotrophic activity useful in the treatment of diseases mediated by the nerve growth factor (NGF) activation
WO2002000222A1 (en) * 2000-06-26 2002-01-03 Novo Nordisk A/S Use of potassium channel agonists for the treatment of cancer
EP1345618B1 (de) * 2000-12-28 2005-03-23 Switch Biotech Aktiengesellschaft Chlorzoxazon zur behandlung von psoriasis
JP2004520396A (ja) * 2001-02-15 2004-07-08 ニューロサーチ、アクティーゼルスカブ 過剰な又は不十分な細胞死によって特徴づけられる疾患の治療
US20020183395A1 (en) 2001-04-04 2002-12-05 Wyeth Methods for treating hyperactive gastric motility
US7148007B2 (en) * 2001-07-24 2006-12-12 Kabushiki Kaisha Toshiba Method for evaluating immunotoxicity of test substance
DE10250870A1 (de) * 2002-10-31 2004-05-13 Switch Biotech Ag Zusammensetzung enthaltend Aktivatoren von IK-Kaliumkanälen und Calcineurin-Antagonisten und deren Verwendung
FR2849773B1 (fr) * 2003-01-15 2006-07-14 Oreal Composition capillaire contenant un 2-alkylidene aminooxy-acetamide, son utilisation pour stimuler la pousse des cheveux et/ou freiner leur chute
WO2004069213A2 (en) * 2003-01-15 2004-08-19 L'oreal Cosmetic composition comprising a 2-alkylideneaminooxyacetamide
US9408405B2 (en) 2003-10-03 2016-08-09 Veijlen N.V. Use of compounds that are able to increase the serum IGF-1 level for the preparation of a therapeutical composition for treatment of various disease states associated with a reduced IGF-1 serum level in humans and animals
DE602004021010D1 (de) 2003-10-03 2009-06-18 Veijlen N V Tierfutterzusammensetzung
WO2008034011A2 (en) 2006-09-13 2008-03-20 Mcw Research Foundation, Inc. Methods of modulating cell proliferation and cyst formation in polycystic kidney and liver diseases
US8232310B2 (en) * 2006-12-29 2012-07-31 Georgetown University Targeting of EWS-FLI1 as anti-tumor therapy
US20120190723A1 (en) * 2010-12-14 2012-07-26 Fatah Kashanchi Viral modulators and processes thereof
CA2821480A1 (en) 2010-12-20 2012-06-28 Astrazeneca Ab 2-carboxamide-4-piperazinyl-benzofuran derivative
NZ700612A (en) 2012-04-12 2016-09-30 Univ Georgetown Methods and compositions for treating ewings sarcoma family of tumors
US9511050B2 (en) 2013-10-24 2016-12-06 Georgetown University Methods and compositions for treating cancer
WO2015160842A1 (en) * 2014-04-14 2015-10-22 Flex Pharma, Inc. Methods and formulatiions of capsaicinoids and capsinoids
MX2016013486A (es) * 2014-04-14 2017-05-10 Flex Pharma Inc Activadores de canales ionicos y metodos de uso.
CN104130175A (zh) * 2014-06-13 2014-11-05 天津科技大学 不同位置取代吲哚酮类衍生物及其应用
CN111777596A (zh) 2014-10-09 2020-10-16 英克特诺治疗公司 吲哚酮化合物及其用途
WO2017172368A1 (en) 2016-03-31 2017-10-05 Oncternal Therapeutics, Inc. Indoline analogs and uses thereof
CN109789127B (zh) 2016-07-29 2022-03-25 英克特诺治疗公司 吲哚啉酮化合物的用途
ES3055314T3 (en) 2017-01-06 2026-02-11 Iovance Biotherapeutics Inc Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof
US11253493B2 (en) 2017-01-23 2022-02-22 Cliff-Cartwright Corporation Compositions and methods affecting exercise performance
CN108017570A (zh) * 2017-12-21 2018-05-11 常州大学 一种靛红的生产方法
CN108403690A (zh) * 2018-05-15 2018-08-17 泰山医学院 一种抑制黑色素瘤细胞增殖的药物及其应用
CN108721297A (zh) * 2018-05-15 2018-11-02 泰山医学院 一种减轻免疫抑制的抗肿瘤药物及其应用
CN113564623A (zh) * 2021-06-17 2021-10-29 福建师范大学 电化学氧化n-取代吲哚衍生物制备靛红化合物的方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06228092A (ja) * 1992-11-17 1994-08-16 E R Squibb & Sons Inc キノリンおよびインドリンのアミノカルボニル（チオカルボニル）およびシアノグアニジン誘導体
JPH08333336A (ja) * 1995-06-07 1996-12-17 Bristol Myers Squibb Co カリウムチャネル誘導因子としての３−置換オキシインドール誘導体

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR65270B (en) * 1978-10-10 1980-07-31 Fujisawa Pharmaceutical Co Isatin derivatives and processes for the preparation thereof
US4322533A (en) * 1980-03-17 1982-03-30 Lesher George Y 1H-Indole-2,3-dione derivatives
US4780477A (en) * 1985-06-08 1988-10-25 Kissei Pharmaceutical Co., Ltd. Isatin compositions having anti-ulcer activities
GB8816944D0 (en) * 1988-07-15 1988-08-17 Sobio Lab Compounds
IE69677B1 (en) * 1989-12-11 1996-10-02 Neurosearch As Isatine derivatives their preparation and use
US5192792A (en) * 1990-12-07 1993-03-09 Warner-Lambert Company Isatine derivatives, and their method of use
US5312928A (en) * 1991-02-11 1994-05-17 Cambridge Neuroscience Calcium channel antagonists and methodology for their identification
JP3419539B2 (ja) * 1993-02-17 2003-06-23 中外製薬株式会社 インドリン−２−オン誘導体
EP1002535A1 (en) * 1998-10-28 2000-05-24 Hrissanthi Ikonomidou New use of glutamate antagonists for the treatment of cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06228092A (ja) * 1992-11-17 1994-08-16 E R Squibb & Sons Inc キノリンおよびインドリンのアミノカルボニル（チオカルボニル）およびシアノグアニジン誘導体
JPH08333336A (ja) * 1995-06-07 1996-12-17 Bristol Myers Squibb Co カリウムチャネル誘導因子としての３−置換オキシインドール誘導体

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
JPN6010023719, ＤＺＹＵＢＥＮＫＯ，Ｖ．Ｇ． ｅｔ ａｌ．, "Ｔｒｉ− ａｎｄ ｔｅｔｒａａｌｋｙｌｉｎｄｏｌｏ［３，２−ｄ］ｔｈｉａｚｏｌｅｓ ａｎｄ ｔｈｅｉｒ ｄｅｒｉｖａｔｉｖｅｓ", Ｚｈｕｒｎａｌ Ｏｒｇａｎｉｃｈｅｓｋｏｉ Ｋｈｉｍｉｉ, 1987, Ｖｏｌ．２３， Ｎｏ．３, ｐ．６３１−６３７ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009227624A (ja) * 2008-03-24 2009-10-08 Fujifilm Corp 新規化合物、光重合性組成物、カラーフィルタ用光重合性組成物、カラーフィルタ、及びその製造方法、固体撮像素子、並びに、平版印刷版原版

Also Published As

Publication number Publication date
AU1648600A (en) 2000-06-26
EP1135123A1 (en) 2001-09-26
US20030114513A1 (en) 2003-06-19
DE69922997D1 (de) 2005-02-03
EP1135123B1 (en) 2004-12-29
WO2000033834A1 (en) 2000-06-15
ATE285769T1 (de) 2005-01-15
DE69922997T2 (de) 2005-12-15
US20020016354A1 (en) 2002-02-07
US6969729B2 (en) 2005-11-29

Similar Documents

Publication Publication Date Title
JP2002531552A (ja) イオンチャネル調節剤としての新規ベンズイミダゾロン−、ベンズオキサゾロン−又はベンゾチアゾロン−誘導体
US6969729B2 (en) Use of isatin derivatives as ion channel activating agents
EP1091942B1 (en) Potassium channel blocking agents
AU2023266373A1 (en) Kv7 channel activators compositions and methods of use
US8252806B2 (en) Potassium channel modulating agents and their medical use
JP2002533318A (ja) イオンチャネル調節剤
KR100492052B1 (ko) 인돌-2,3-디온-3-옥심유도체,이의제조방법및이를포함하는약제학적조성물
TW200806650A (en) P38 inhibitors and methods of use thereof
JP2008534472A (ja) カリウムチャンネル調節剤としてのピラゾリル−ピリミジン及びその医学的使用
US20090036475A1 (en) Pyrazolyl-Pyrimidines as Potassium Channel Modulating Agents and Their Medical Use
JP2002531539A (ja) イオンチャネル調節剤
JP2002544258A (ja) イオンチャネル調節剤
CN101115736A (zh) 钾通道调节剂和它们的医药用途
UA129244C2 (uk) Спосіб застосування тризаміщених похідних бензотриазолу як інгібіторів дигідрооротатоксигенази
JP2002544268A (ja) イオンチャネル調節剤
JP2002509885A (ja) 治療に使用するためのインドール−２，３−ジオン−３−オキシム誘導体
EP0623620B1 (fr) Dérivés de pyrrolopyrazines à activité 5-HT3
MXPA98004365A (en) Novel indole-2,3-dione-3-oxime derivatives

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20061129

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20061129

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20100519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20100525

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20101109